stroke - search results
If you're not happy with the results, please do another search
LAAC-related ischaemic stroke “less severe and less fatal” than with DOACs in AF patients
Ischaemic strokes in atrial fibrillation (AF) patients are less often disabling or fatal if they have been treated with left atrial appendage closure procedure...
ARTESIA shows reduced rate of stroke and embolism in sub-clinical AF patients receiving apixaban
Use of apixaban in patients with sub-clinical atrial fibrillation (AF) resulted in a lower risk of stroke or systemic embolism than aspirin, but a...
ESC 2023: Study finds link between fitness and incidence of AF and stroke
Physical fitness is linked with a lower likelihood of developing atrial fibrillation (AF) and stroke, a study of more than 15,000 people, to be...
Shopping trolley AF sensor “holds promise for stroke prevention”
The use of embedded electrocardiogram (ECG) sensors in shopping trolley handles could effectively identify individuals with previously undiagnosed atrial fibrillation (AF). This is among...
Early anticoagulation after ischaemic stroke “reasonable” and “unlikely to cause harm”
An international clinical trial presented today at the European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany) has demonstrated that—in people with ischaemic stroke...
EHRA 2023: Statin use associated with lower risk of stroke in patients with AF
A region-wide study in more than 50,000 patients with atrial fibrillation (AF) has found reduced risks of stroke and transient ischaemic attack in those...
Early rhythm control aids recurrent stroke prevention in patients with AF
Early rhythm control one year after atrial fibrillation (AF) diagnosis has been found to be beneficial in preventing recurrent stroke in patients with incident...
Continuous monitoring detects atrial fibrillation in 20% of atherosclerotic stroke survivors
In a study presented yesterday at the International Stroke Conference (ISC; 8–10 February, Dallas, USA), irregular heart rhythms were detected in roughly one in...
Biobeat receives FDA clearance for remote stroke volume and cardiac output monitoring devices
Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced today that its wearable remote patient monitoring devices have...
Measurement of left atrial mechanical function found to improve stroke prediction
A cohort study of more than 4,500 persons without a history of atrial fibrillation (AF) or stroke has found that measuring left atrial mechanical...
LeAAPS trial to explore benefit of left atrial appendage occlusion in cardiac surgery patients...
Researchers are to investigate the safety and efficacy of performing left atrial appendage occlusion in patients at high risk for atrial fibrillation (AF) who...
Rates of stroke and embolism lower with apixaban compared to rivaroxaban
In a large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease, those receiving apixaban had a lower risk for ischaemic...
New data from STROKE AF trial shared at HRS 2022
Medtronic has announced new data from the STROKE AF clinical trial, showing that large and small vessel ischaemic stroke patients who receive short-term or...
Remote blood pressure monitoring beneficial for stroke survivors in under-resourced areas
A new strategy using telehealth to monitor blood pressure at home for several months immediately after a stroke had a positive impact on patient engagement and blood...
Alternative timing method for direct oral anticoagulants following ischaemic stroke with atrial fibrillation deemed...
A new timely practice—known as the “1-2-3-4-day” rule—for the administration of direct oral anticoagulants (DOACs) in patients after acute ischaemic stroke or transient ischaemic...
Study highlights temporal relationship between AF and stroke
Medtronic has announced the publication of a study demonstrating, through the use of a continuous rhythm monitoring device, that atrial fibrillation (AF) is directly...
Continuous heart rhythm monitoring “does not prevent strokes in those at risk”
Continuous heart rhythm monitoring—with anticoagulation if atrial fibrillation (AF) is detected—does not prevent strokes in those at risk. That is the finding of the...
HRS 2021: DOACs reduce risk of stroke in patients undergoing left ventricular RFA
Use of direct oral anticoagulants (DOACs) in patients undergoing ventricular tachycardia radio frequency ablation (RFA) is associated with a reduced risk of transient ischaemic...
TVT 2021: Two-year PINNACLE FLX results report low rate of ischaemic stroke for Watchman...
Two-year results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation Watchman FLX (Boston Scientific) left atrial appendage closure...
Medtronic announces publication of STROKE AF trial results
Medtronic has announced clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal LINQ insertable cardiac monitor (ICM) to detect...
ACC.21: Registry data show low rate of stroke at one year following LAAO with...
Transcatheter left atrial appendage occlusion (LAAO) with a Watchman (Boston Scientific) device was associated with a low rate of stroke at one year, even...
ACC.21: LAAO after heart surgery offers “new paradigm” for stroke prevention in AF patients
Patients with an elevated risk of stroke due to arrhythmia or atrial fibrillation (AF), were much less likely to suffer a stroke after undergoing...
Heavy alcohol consumption leads to higher stroke risk in AF patients
Fourteen drinks a week is linked with a higher risk of stroke and embolism in patients with atrial fibrillation (AF), according to research published...
BMJ study proves efficacy of Coala Heart Monitor as part of cryptogenic stroke management
Coala Life has announced the results of a late breaking trial on cryptogenic stroke patients. In the TEASE-study, recently published in the British Medical...
Air pollution exposure multiplies risk of stroke in AF patients
Sufferers of atrial fibrillation (AF) who are exposed to greater levels of pollution have a 1.2-fold higher risk of stroke than their peers who...
ESC Congress 2020: Smoking cessation linked to reduced stroke risk in AF patients
Research presented at the ESC Congress 2020 (Virtual, 29 August–1 September) suggests that, among atrial fibrillation (AF) patients, those who quit smoking were 30%...
LIVE from SNIS: Bridging therapy independently predicts haemorrhagic complications in atrial fibrillation associated stroke
Exposure to bridging therapy independently predicts haemorrhagic complications—without improving functional outcomes—in patients with atrial fibrillation (AF) associated stroke. The findings from this retrospective, registry...
Continuous electrocardiogram monitoring post-stroke patients uncovers AF in 4.6% of patients
Screening patients in a primary care setting over one year after occurrence of a stroke using seven-day Holter monitoring uncovered atrial fibrillation (AF) in 4.6%...
Abbott announces trial to assess new therapy option for stroke
Abbott has announced approval from the US Food and Drug Administration (FDA) for the CATALYST trial to examine its Amplatzer Amulet device compared to...
BIBA Briefings: Longest and largest follow-up data for Watchman supports its role in stroke...
Data from the CAP and CAP2 registries—which contain the longest and largest follow-up of patients—add to previous evidence that left atrial appendage closure (LAAC)...
Left atrial appendage closure associated with a decreased stroke risk in AF patients
Left atrial appendage closure (LAAC) via implanted device was associated with a decreased risk of admission for stroke, compared with the expected risk without...
New technology improves atrial fibrillation detection after stroke
A new method of evaluating irregular heartbeats outperformed the approach that is currently used widely in stroke units to detect instances of atrial fibrillation.
The...
Boston Scientific initiates trial comparing left atrial appendage closure to direct oral anticoagulants for...
According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...
Targeted blood pressure management helps to reduce strokes in patients with HVAD
An analysis on the impact of stroke severity in patients receiving the HeartWare HVAD system (Medtronic) as destination therapy shows that targeted blood pressure...
First AI-driven wearable heart monitor that prevents heart disease and stroke to be released
Cambridge Heartwear is announcing the launch of their company and release of their Heartsense monitor in 2019. In the US, strokes are among the...
AI-based solution to screen atrial fibrillation to improve stroke prevention
Maisense, a start-up company specialising in stroke prevention, has recently introduced an AI-based solution that can screen stroke through early detection of atrial fibrillation...
Stroke – the need for interdisciplinary concepts
The link between cardiac diseases and stroke is well known and reported. Wolfram Döhner writes in Cardiac Rhythm News about the needs for interdisciplinary...
RHYTHM study published revealing link between total AF burden and stroke risk
iRhythm Technologies has announced results of a study which utilised Zio by iRhythm, an extended continuous cardiac monitoring system, to provide a comprehensive picture...
New real-world study finds long-term rivaroxaban use resulted in fewer strokes and systemic emboli...
Two-year results show rivaroxaban was associated with reduced stroke and systemic embolism versus warfarin, without altering risk of major bleeding. The study evaluated efficacy...
HAVOC: new score developed to identify AF patients at higher risk of stroke
The HAVOC score was developed following the CRYSTAL-AF study, to see if there was an easier way to identify which patients with atrial fibrillation...
Stroke prevention drugs may help reduce dementia risk for atrial fibrillation patients
Patients with atrial fibrillation could reduce the risk of dementia by taking stroke prevention medications, according to recommendations published online in EP Europace1, a...
New long-term data show improved survival and lower rates of stroke and pump thrombosis...
New late-breaking clinical trial data from the MOMENTUM 3 clinical study shows overall survival of 83% at 2-years and marked improvement in clinical outcomes for...
New-onset atrial fibrillation after CABG significantly increases the risk of death and stroke in...
New data from the EXCEL trial, which found that percutaneous coronary intervention (PCI) was non-inferior to coronary artery bypass grafting (CABG) at three years...
African Americans with atrial fibrillation at significantly higher risk of stroke
African Americans with atrial fibrillation (AF) have a significantly higher risk of stroke than Caucasians with the condition, according to new research published in HeartRhythm by...
Evolocumab becomes first FDA-approved PCSK9 inhibitor for prevention of MI and stroke
Following a priority review by US Food and Drug Administration (FDA), evolocumab has received FDA approval in the USA. The drug is a PCSK9...
Low-risk AF for stroke identified with CHA2DS2-VASc Score
A Korean nationwide cohort study by Tae-Hoon Kim et al has shown that truly low-risk Asian patients with atrial fibrillation (AF) for stroke can...
Use of apixaban prior to cardioversion reduces risk of stroke
According to the results of the EMANATE trial, patients with atrial fibrillation (AF) who receive apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) before undergoing elective cardioversion of...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and myocardial infarction in...
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...
ESC 2017: Apixaban lowers risk of stroke in atrial fibrillation patients undergoing cardioversion
Data from the EMANATE trial, which was presented at a Hot Line session of the European Society of Cardiology (ESC) congress (26–30 August, Barcelona,...
Europace 2017: Thrombus formation on left atrial appendage occlusion devices strongly associated with higher...
A French multicentre analysis of left atrial appendage (LAA) occlusion for stroke prevention in atrial fibrillation patients has found a 5.3% rate of thrombus...
Europace 2017: Stroke history higher in asymptomatic versus symptomatic atrial fibrillation patients
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with symptoms, according to results from the GLORIA-AF registry...
Breastfeeding may reduce a mother’s heart attack and stroke risk
Breastfeeding may reduce a mother’s risk of having a heart attack or stroke later in life, according to new research published in of the...
HRS 2017: Watchman prevents stroke even in high-risk patients: One-year follow-up of EWOLUTION registry...
Left atrial appendage closure with the Watchman device (Boston Scientific) is safe and effective at stroke prevention, with a high implant and sealing success,...
Four out of 10 AF patients may not receive necessary stroke-prevention medication
Many patients with an irregular heartbeat, known as atrial fibrillation, are not receiving recommended blood thinning medication they need to prevent strokes, according to...
Surgical left atrial appendage occlusion reduces thromboembolic stroke and mortality in older AF patients
Surgical left atrial appendage occlusion (LAAO) is associated with a reduction of thromboembolism and all-cause mortality among older atrial fibrillation (AF) patients undergoing cardiac...
Janssen and Premier to initiate stroke risk management study among AF patients
Janssen Pharmaceuticals has collaborated with Premier on the first and largest study of its kind to address an unmet medical need for hospitalised patients...
ACC 2017: Anticoagulant treatment may be unnecessary for stroke prevention following ablation for atrial...
For patients with persistent atrial fibrillation or those who are at high risk for recurring atrial fibrillation, catheter ablation is recommended, followed most often...
New multidisciplinary care pathway helps to reduce the risk of recurrent stroke in cryptogenic...
A growing body of evidence suggests that the underlying cause for many cryptogenic strokes is atrial fibrillation (AF). However, many of these patients do...
Charity believes NHS programme will leave hundreds of atrial fibrillation patients at risk of...
Arrhythmia Alliance, the UK-based heart rhythm charity, is calling on NHS England to reconsider a programme that it says will mean the “hundreds” of...
Patent foramen ovale closure is more effective than medical management in preventing recurrent stroke
Final results from the RESPECT trial found that percutaneously closing a patent foramen ovale (PFO) using the Amplatzer PFO Occluder (St Jude Medical) was...
Short episodes of atrial fibrillation may not increase risk of stroke
People with pacemakers or defibrillators who experience only short episodes of atrial fibrillation have a very low risk of stroke, suggesting that anticoagulants in...
ESC 2016: “User-friendly” risk score may help to better identify atrial fibrillation patients at...
A new risk score, based on data from GARFIELD-AF (Global anticoagulation registry in the field), may be superior to the CHA2DS2-VASc score at predicting...
Daiichi Sankyo PREFER in AF registry suggests increased stroke risk among diabetic atrial fibrillation...
Daiichi Sankyo has announced data from new sub-analyses of the Prevention of thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF) patient registry, which...
Educational supplement: LAA closure for stroke prophylaxis in atrial fibrillation
This educational supplement is only for readers in countries outside France, Japan and the USA
In this educational supplement, sponsored by Boston Scientific, Cardiac Rhythm News explores left...
Digital strategies show promise for emergency heart and stroke care
Mobile devices, social media, visual media and crowdsourcing have the potential to improve emergency care for cardiac arrests, heart attacks and strokes, according to...
AF patients with intermediate-to-high-risk of stroke often prescribed aspirin instead of anticoagulants
More than one-in-three patients with atrial fibrillation with an intermediate-to-high-risk of stroke are prescribed aspirin instead of oral anticoagulants, despite guidelines recommending the use...
Over a quarter of a million UK AF patients receiving inadequate stroke prevention treatment
Over 260,000 people with atrial fibrillation (AF) in the UK are receiving either no preventative treatment, or are still taking only aspirin, no longer...
Atrial fibrillation patients at highest stroke risk not prescribed necessary medication
Nearly half of all atrial fibrillation patients at the highest risk for stroke are not being prescribed blood thinners by their cardiologists, according to a new study.
German public health body grant once-daily edoxaban indication for prevention of stroke in non-valvular...
The German Federal Joint Committee (Gemeinsamer Bundesausschuss-G-BA) has granted Daiichi Sankyo's edoxaban (Lixiana) an indication of a minor additional benefit.
Adults with congenital heart defects at considerably higher risk of stroke
A study has shown heart failure, diabetes and recent heart attacks to be the strongest predictors of stroke caused by a blocked artery.
Pacemakers identify atrial fibrillation and enable initiation of stroke prevention
According to research presented at Acute Cardiovascular Care 2015, pacemaker checks are a good way to identify new cases of atrial fibrillation so that anticoagulation can be started to prevent strokes.
NICE recommends once-daily Lixiana (edoxaban) for preventing stroke and systemic embolism in non-valvular atrial...
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism in patients suffering from atrial fibrillation.
NICE recommends once-daily edoxaban for preventing stroke and systemic embolism in non-valvular atrial fibrillation...
NICE Final Appraisal Determination recommends that edoxaban is a cost-effective use of NHS resources.
Addressing social factors critical for continued fight against heart disease and stroke in the...
Deaths from heart attacks, strokes and other heart diseases have been declining, but social factors, including race, income, environment and education could reverse that trend.
One-year outcomes on stroke prevention in patients with newly-diagnosed atrial fibrillation to be presented...
Real-life data on stroke prevention from 17,200 patients will provide information on how patient risk profiles and quality of vitamin K antagonist control are associated with increased mortality and stroke in patients with newly diagnosed atrial fibrillation.
Benefit of anticoagulation in AF patients with a low risk of stroke questioned
The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low risk of stroke.
Targeting the left atrial appendage for AF-related stroke prevention: Why the heart team is...
Sacha Salzberg cardiovascular surgeon (Heart Clinic Hirslanden, Cardiac Surgery Unit, Zurich, Switzerland) comments on catheter-based and surgical approaches for left atrial appendage occlusion as...
Edoxaban approved for prevention of stroke and systemic embolism in non-valvular AF and treatment...
Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and treatment of venous thromboembolism in deep vein thrombosis.
Many atrial fibrillation patients at high risk of stroke fail to receive guideline-recommended oral...
First phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA-AF Registry programme.
Real-world study shows effectiveness of Reveal LINQ to detect atrial fibrillation in cryptogenic stroke...
New data demonstrate cost-effectiveness of long-term, continuous cardiac monitoring with potential to prevent recurrent strokes.
Real-world multicentre study shows positive outcomes with left atrial appendage occlusion for stroke prevention...
The largest study using the Amplatzer Cardiac Plug (St Jude Medical) for left atrial appendage occlusion has shown a high procedural success rate and favourable outcomes for prevention of atrial fibrillation-related thromboembolism.
FDA approves Savaysa for reduction of stroke risk in non-valvular atrial fibrillation and for...
Savaysa (edoxaban) is an oral, once-daily selective factor Xa inhibitor, designed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
Bayer collaborates on phase III study to evaluate Xarelto in embolic stroke patients
In addition, Xarelto (rivaroxaban) label now includes guidance for use in patients with atrial fibrillation undergoing cardioversion.
First trial of oral anticoagulant to prevent recurrent stroke due to a blood clot...
The first patient has been enrolled in the RE-SPECT ESUS phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent embolic stroke of undetermined source.
Watchman presents possible alternative to warfarin for stroke prevention in patients with atrial fibrillation
Study examines the long-term efficacy and safety of Boston Scientific's Watchman device to achieve left atrial appendage closure in patients with atrial fibrillation.
Survey uncovers need to raise awareness of link between atrial fibrillation and the impact...
A survey issued by the Heart Rhythm Society and National Stroke Association in collaboration with Boehringer Ingelheim has found there are information gaps regarding the impact of AF-related stroke - among AF patients, physicians and caregivers - including communication barriers, challenges with patient education, misperceptions about treatment compliance, and outcomes related to the impact of stroke on one's life.
Permanent AF doubles risk of stroke compared to paroxysmal AF
Permanent atrial fibrillation (AF) doubles the risk of stroke compared to paroxysmal AF, according to research in more than 6,000 patients presented at European Society of Cardiology Congress. The findings suggest that a simple clinical assessment of the type of AF can help doctors to better estimate stroke risk.
Study finds Medtronic insertable cardiac monitors detect AF in stroke patients better than standard...
The CRYSTAL AF trial found that continuous cardiac monitoring with the Reveal XT insertable cardiac monitor was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes.
NICE no longer recommends aspirin alone for reducing risk of stroke in AF patients
Updated National Institute for Health and Care Excellence (NICE) guidelines no longer recommend aspirin use alone, solely to reduce the risk of stroke in patients with atrial fibrillation (AF).
First patient enrolled in Stroke Feasibility Study
The Stroke Feasibility Study is the first US clinical study to evaluate the safety of a novel epicardial-based left atrial appendage closure device for stroke prevention in atrial fibrillation patients.
New registry data highlight substantial global differences in stroke prevention for patients with an...
GLORIA-AF registry programme shows half of patients in China with an irregular heartbeat suboptimally protected against potentially devastating stroke.
Eliquis (apixaban) recommended for prevention of stroke
Eliquis (apixaban) has been recommended for continued use for prevention of stroke / systemic embolism in patients with non valvular atrial fibrillation while undergoing cardioversion by European Medicines Agency's Committee for Medicinal Products for Human Use.
Apixaban is cost-effective compared with standard of care for stroke prevention in atrial fibrillation
Based on randomised trial data and from the UK payer perspective, apixaban is a cost-effective alternative to warfarin and aspirin for stroke prevention in atrial fibrillation patients.
New onset atrial fibrillation after TAVI does not increase rate of stroke or mortality
A new study has found that new onset atrial fibrillation after transcatheter aortic valve implantation (TAVI) does not increase significantly the rate of stroke or mortality at 30-days and one-year follow-up.
Outbursts of anger linked to greater risk of heart attacks and strokes
Outbursts of anger may trigger heart attacks, strokes and other cardiovascular problems in the two hours immediately afterwards, according to the first study to systematically evaluate previous research into the link between the extreme emotion and all cardiovascular outcomes.
Subanalysis of phase 3 ARISTOTLE shows apixaban reduced risk of stroke vs. warfarin in...
The subanalysis shows that apixaban was more effective than warfarin in reducing the risk of stroke or systemic embolism, was associated with less major bleeding, less total bleeding and less intracranial haemorrhage, regardless of age and in reducing all-cause mortality across age groups.
Detection of atrial fibrillation with insertable cardiac monitors is superior to standard monitoring in...
Results from the CRYSTAL AF trial have shown that atrial fibrillation in patients with cryptogenic stroke is better detected with insertable cardiac monitors than standard monitoring at six, 12 and 36 months.
New data support use of Zio Patch to identify cardiac arrhythmias in stroke and...
New study data support the use of the Zio Patch to help identify underlying cardiac arrhythmias in patients who have had a stroke or transient ischaemic attack. The Zio Patch enables long-term continuous monitoring to detect sporadic heart rhythm disturbances, including atrial fibrillation.
Aspirin still overprescribed for stroke prevention in atrial fibrillation
According to a recent study, aspirin is still overprescribed for stroke prevention in atrial fibrillation despite the potential for dangerous side effects.
Does the anatomy of left atrial appendage correlate with the risk of stroke?
Luigi Di Biase writes for Cardiac Rhythm News on the results of a study that identified four different left atrial appendage morphologies and its relationship with the risk of stroke in atrial fibrillation patients. "These results could have a relevant impact on the oral anticoagulation management and occlusion device management of atrial fibrillation patients with an intermediate risk for stroke," writes Di Biase.
Edoxaban not inferior to warfarin in stroke prevention for atrial fibrillation patients
Results from the ENGAGE AF-TIMI 48 clinical trial have found that the investigational, oral, once daily direct factor Xa-inhibitor edoxaban (Lixiana, Daiichi-Sankyo) met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation.
HAS-BLED score more accurate than stroke scores at predicting major bleeding in anticoagulated AF...
A new study has identified that, in anticoagulated patients with atrial fibrillation (AF), the HAS-BLED score has better prediction accuracy for major bleeding than the CHADS2 or CHA2DS2-VASc scores.
Catheter ablation may reduce stroke risk in atrial fibrillation patients
A first of its kind study has shown that patients with atrial fibrillation who undergo catheter ablation have a lower stroke risk than patients who do not undergo the procedure independent of CHADS2 score.
GARFIELD registry shows antithrombotic agents not optimally used to prevent stroke
The findings, from eight abstracts presented this week at the ESC congress 2013, collectively show that anticoagulant therapy which is known to significantly lower stroke risk in AF patients-is consistently under-utilised among those at-risk atrial fibrillation patients.
Stroke or systemic embolism uncommon in AF patients treated with apixaban within 30 days...
Results of a post-hoc subanalysis from the phase III ARISTOTLE trial have shown that stroke or systemic embolism and major bleeding were uncommon within 30 days in non-valvular atrial fibrillation patients who undertook a medical procedure.
Treatments to prevent stroke in atrial fibrillation patients
Patrick Ellinor, director Cardiac Step Down Unit, Massachusetts General Hospital Corrigan Minehan Heart Centre (Boston, USA) discusses different treatment options to prevent stroke in...
New risk assessment tool to predict stroke in patients with atrial fibrillation
Model will give physicians more reliable guidance in making therapeutic decisions for stroke prevention.
Effectiveness of left atrial appendage exclusion, ligation and occlusion in reducing stroke risk in...
Andre d'Avila and Arash Aryana write on three different left atrial appendage strategies aimed to reduce stroke risk in atrial fibrillation patients. d'Avila presented this analysis at Heart Rhythm (Denver, USA, 8-5 May 2013).
UK’s NICE publishes final guidance recommending apixaban to prevent stroke in non-valvular atrial fibrillation...
On 27 February, the UK's National Institute for Health and Clinical Excellence (NICE) released final guidance recommending apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) as an option for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation.
Massachusetts General Hospital launches the Institute for Heart, Vascular and Stroke Care
According to a Massachussetts General Hospital press release this is one of the only institutes in the world to integrate cardiovascular and cerebrovascular care.
The Scottish Medicines Consortium accepts apixaban for prevention of Stroke in non-valvular atrial fibrillation...
The Scottish Medicines Consortium has accepted the novel oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb / Pfizer) for use within NHS Scotland for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.
St Jude Medical receives the CE mark for the Amplatzer Amulet Left Atrial Appendage...
The Amulet device is used to close the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation.
FDA approves apixaban to reduce the risk of stroke in AF patients
On 28 December 2012, the FDA approved the anticlotting drug apixaban (Eliquis, Bristol-Myers Squibb), an oral tablet used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Apixaban now available in the UK for the prevention of stroke and systemic embolism...
The oral anticoagulant is a new prescription only treatment option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors such as: prior stroke or transient ischaemic attack; age 75 years or older; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Mobile Cardiac Outpatient Telemetry helps to detect paroxysmal atrial fibrillation in cryptogenic stroke patients
A study published in the Journal of the Neurological Sciences has found that Mobile Cardiac Outpatient Telemetry (MCOT) supports the detection of a high rate of occult paroxysmal atrial fibrillation (PAF) in cryptogenic stroke and transient ischaemic attack (TIA) patients.
European Commission approves apixaban for prevention of stroke and systemic embolism in non-valvular atrial...
The European approval for apixaban is supported by the pivotal phase 3 trials ARISTOTLE and AVERROES, which evaluated approximately 24,000 patients with non-valvular atrial fibrillation.
Apixaban receives CHMP positive opinion for the prevention of stroke and systemic embolism in...
The positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) was based on the pivotal ARISTOTLE and AVERROES studies, which evaluated apixaban in approximately 24,000 patients with non-valvular atrial fibrillation.
Should female gender be included in risk scores for stroke?
Female gender is only a significant risk for stroke in patients with atrial fibrillation among those aged ≥75 years-indicating its inclusion in risk scores for stroke may not be required, according to study presented at the ESC annual meeting.
Female gender increases stroke risk in older AF patients by 20%
According to a study presented at the annual meeting of the European Society of Cardiology (ESC), 25-29 August, Munich, Germany, being female increases the risk of stroke in patients with atrial fibrillation who are >75 years by 20%
Dabigatran may be more effective in the long term than rivaroxaban in stroke prevention...
The analysis, based on two large scale trials including more than 32.000 patients combined, suggests that patients treated with dabigatran may have lower rates of ischaemic stroke and intracranial haemorrhage, and also accumulate lower costs from acute care and long-term follow-up over their lifetime than patients treated with rivaroxaban.
UK’s NICE releases final guidance on rivaroxaban for prevention of stroke and systemic embolism...
The guidance recommends rivaroxaban for people with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack.
Watchman device shows 75% reduction in stroke risk in patients with atrial fibrillation not...
Vivek Reddy, New York, USA, presented results from the ASA Plavix (ASAP) study of the Watchman Left Atrial Appendage Closure (LAAC) device (Boston Scientific) during a late-breaking session at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston, USA.
Non-surgical procedure offers patients with atrial fibrillation who cannot take blood thinners an alternative...
The procedure, known as left atrial appendage occlusion, is performed using the FDA-approved Lariat Suture Delivery Device (SentreHeart).
Stroke risk high when anti-clotting drugs stopped
Some patients with certain types of atrial fibrillation who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging Science Series webinar.
Prolonged QTc significantly increases the risk of stroke
Elsayed Soliman, Winston-Salem, USA, and colleagues have found that prolonged QTc is associated with a significantly increased risk of stroke, indicating that drugs that prolong QTc may need to be investigated for a potential association with stroke.
GLORIA-AF registry to explore use of antithrombotic therapy in 56,000 patients with atrial fibrillation...
The registry programme will collect important data on the safety and comparative effectiveness of antithrombotic treatments, including vitamin K antagonist warfarin, acetylsalicylic acid and novel oral anticoagulants, such as dabigatran etexilate.
ROCKET-AF sub-analysis results presented at International Stroke Conference
A sub-analysis of data from the ROCKET-AF trial presented at the American Stroke Association's International Stroke Conference 2012 shows that rivaroxaban (Xarelto, Bayer Healthcare) might be better at preventing clot-related strokes in patients with atrial fibrillation while minimising the risk of causing a bleeding stroke.
Paroxysmal atrial fibrillation may account for some unexplained strokes
Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012.
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, increase the risk of stroke
A new study, published in the New England Journal of Medicine, has added weight to the view that subclinical atrial fibrillation is a possible cause of cryptogenic stroke after finding that 13% of strokes and systemic embolisms in the study population were associated with subclinical atrial tachyarrhythmias.
Pan-European stroke prevention in atrial fibrillation registry PREFER in AF enrols first patient
The registry will gather information from valvular and non-valvular atrial fibrillation patients. It will also track the impact of new anticoagulant therapies on stroke prevention, in addition to collating insights into patients' satisfaction with their entire atrial fibrillation management and the overall health economic burden of atrial fibrillation across Europe.
NICE needs more evidence on rivaroxaban for prevention of stroke in atrial fibrillation patients
In preliminary recommendations published on 9 January, NICE is asking Bayer HealthCare for more information on its product rivaroxaban (Xarelto), for the prevention of stroke and systemic embolism in people with atrial fibrillation.
More work needed to reduce strokes due to atrial fibrillation in UK
A study published in BMJ Open has found that although the number of strokes has fallen in the UK, more needs to be done to reduce the risk of stroke in patients with atrial fibrillation. Additionally, it seems that while the use of anticoagulants does not increase with increasing CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score in patients with atrial fibrillation, the use of antiplatelets does increase
NICE recommends dabigatran for prevention of stroke in AF patients
In a final draft guidance published on 1 November the UK National Institute for Health and Clinical Excellence (NICE) has recommended dabigatran (Pradaxa, Boehringer Ingelheim), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in people with atrial fibrillation.
FDA approves rivaroxaban to prevent stroke in non-valvular atrial fibrillation patients
The Food and Drug Administration's approval is largely based on the results from the ROCKET-AF trial, a double-blind global phase III study that showed the safety and efficacy of rivaroxaban (Xarelto, Bayer Healthcare).
Atrial fibrillation undertreated as one of the major risk factors for stroke in the...
Despite significant improvements in stroke prevention over the past decade, and a fall in incidence and deaths, UK doctors are still undertreating one of the major risk factors-atrial fibrillation-reveals research published in BMJ Open.
Novel anticoagulant apixaban reduces stroke and major bleeding compared with warfarin in AF patients
New data from the ARISTOTLE study showed that the rate of haemorrhagic stroke in the apixaban group was 49% lower and the rate of ischaemic stroke was 8% lower than in the warfarin group. Results were presented by Christopher Granger, USA, at the European Society of Cardiology (ESC) Congress (27-31 August 2011, Paris, France).
Eliquis (apixaban) superior to warfarin for the reduction of stroke, major bleeding and mortality,...
Eliquis (Bristol-Myers Squibb and Pfizer), compared to standard of care warfarin, significantly reduced risk of stroke or systemic embolism by 21%, risk of major bleeding by 31% and mortality by 11%.
Dabigatran etexilate recommended for approval for stroke prevention in AF patients in Europe
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dabigatran etexilate (Boehringer Ingelheim's Pradaxa) in the member states of the European Union for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk factors.
Apixaban superior to aspirin in reducing stroke and systemic embolism in patients with atrial...
Bristol-Myers Squibb and Pfizer announced the full results of the AVERROES study of apixaban in The New England Journal of Medicine.
Apixaban reduces stroke by more than 50% in AF patients
In atrial fibrillation (AF) patients unsuitable for a vitamin K antagonist, apixaban reduces stroke by more than 50% compared to acetylsalicylic acid without a significant increase in major bleeding.
New trial studies link between stroke and atrial fibrillation
The CRYSTAL AF trial will enrol approximately 450 people who have been diagnosed with a cryptogenic stroke across 55 centres.
Rivaroxaban comparable to warfarin in preventing stroke
The new drug does not increase bleeding risk among atrial fibrillation patients, according to results of the ROCKET AF trial presented at the American Heart Association's Scientific Sessions.
ASSERT study demonstrates effectiveness of implantable device monitoring in predicting stroke
Pacemaker patients who have device-detected arrhythmias are approximately 2.5 times more likely to have a stroke than patients who do not have device-detected arrhythmias.
FDA approves dabigatran to prevent stroke in atrial fibrillation patients
The FDA approved on 19 October 2010 dabigatran etexilate (Pradaxa, Boehringer Ingelheim) for the prevention of stroke and blood clots in patients with atrial fibrillation.
FDA advisory committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial...
Dabigatran etexilate may offer patients and doctors the first new treatment option for stroke prevention in atrial fibrillation in more than 50 years.
Analysis of ATHENA shows stroke reduction with dronedarone
Patients receiving dronedarone for atrial fibrillation on top of adequate antithrombotic medication presented a significantly lower incidence of stroke, according to Stefan Hohnloser.
RE-LY: Dabigatran reduces incidence of stroke and systemic embolism
The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study.
deCODE discovers second common genetic risk factor for AF and stroke
The new sequence is in the ZFHX3 gene on chromosome 16q22, and the one third of people of European descent who carry one copy are at 20% greater risk of AF and stroke.
Researchers identify stroke predictors in black patients
Predictors of atrial fibrillation might offer physicians a better way to prevent stroke in blacks, according to a new study performed in Winston-Salem, USA.
Novel device cuts stroke risk in patients with atrial fibrillation
The Watchman, an expandable nitinol cage which blocks blood clots that typically form in the left atrial appendage, may offer alternative to blood-thinning medications.
ATHENA data suggest decrease in stroke risk with dronedarone for AF
Results from a post-hoc analysis of the data from the ATHENA trial show that dronedarone reduces stroke risk in patients with atrial fibrillation.
AF after mitral valve surgery “has a strong negative influence on survival”
The occurrence of atrial fibrillation (AF) after mitral valve surgery may be more harmful than previously thought, the authors of a research paper in...
Large registry confirms promising safety performance for PFA
Analysis of outcomes of more than 17,000 patients receiving pulsed field ablation (PFA) using the Farapulse (Boston Scientific) device reinforce the safety profile of...
SELECT trial shows cardiovascular risk reduction in non-diabetics taking semaglutide
Results of the SELECT clinical trial, presented at the American Heart Association’s 2023 Scientific Sessions (11–13 November, Philadelphia, USA), have shown that overweight or...
CONFORMAL EFS results shared out to one year at TCT 2023
Conformal Medical has announced positive one-year results from the company's CONFORMAL Early Feasibility Study (EFS).
William Gray (Lankenau Heart Institute, Wynnewood, USA) presented the Conformal...
No difference in outcomes for AF patients undergoing LAAO and TAVI at the same...
Patients with atrial fibrillation (AF) undergoing a transcatheter aortic valve implantation (TAVI) at the same time as a left atrial appendage occlusion (LAAO) procedure...
Boston Scientific launches LUX-Dx II+ ICM
Boston Scientific today launched the LUX-Dx II+ insertable cardiac monitor (ICM) system, describing it as a next-generation insertable monitor for long-term monitoring of arrhythmias...
TactiFlex ablation catheter used in first Canadian case
Abbott has announced that the company's TactiFlex ablation catheter has been used for the first time in Canada at the Foothills Medical Centre in...
AZALEA-TIMI 71 Phase 2 study ends early after “overwhelming” endpoint reduction
Anthos Therapeutics has announced that the AZALEA-TIMI 71 Phase 2 study has been stopped early due to an “overwhelming” reduction in the composite of...
Switching to NOACs in frail AF patients associated with more bleeding compared to VKAs
Switching vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) in frail elderly patients with atrial fibrillation (AF) is associated...
Watchman FLX Pro gains US FDA approval
Boston Scientific has received US Food and Drug Administration (FDA) approval for the latest-generation Watchman FLX Pro left atrial appendage closure (LAAC) device.
The device,...
ESC 2023: Anticoagulation should not be used in patients with AHRE until AF is...
Oral anticoagulation in patients with atrial high rate episodes (AHRE) increases bleeding without reducing a composite outcome of stroke, systemic embolism or cardiovascular death.
This...
AI model may improve detection of atrial septal defect
An artificial intelligence (AI) model may be more efficient at detecting signatures of atrial septal defect (ASD) in electrocardiograms (ECG) than traditional methods.
This is...
Extreme temperatures and particulate pollution may increase MI mortality risk
The combination of soaring heat and fine particulate pollution may double the risk of myocardial infarction (MI) mortality, according to a new study of...
Append Medical raises US$4.35 million in initial closing of extended series A round
Append Medical has raised US$4.35 million as part of an extended series A round, which will be used to support the company's first-in-human trials of Appligator.
Investors include...
US FDA approves Biotronik’s Amvia Edge portfolio
Biotronik has announced US Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge pacemakers and cardiac resynchronisation therapy pacemaker (CRT-P).
In a...
Complication and mortality rates for catheter ablation of AF have declined over the last...
Procedure-related complications and mortality rates associated with catheter ablation of atrial fibrillation (AF) are low and have declined in the past decade, conclude the...
Conformal Medical completes series D financing round
Conformal Medical has announced the successful completion of its series D funding round, raising a total of $35 million. The company is developing the...
HRS 2023: Dynamic monitoring “improves access to care for AF patients”
Findings from a new clinical trial support use of implantable cardiac monitors (ICM) as a standard of care in managing patients with complex cardiac...
US FDA approves Abbott’s TactiFlex ablation catheter
Abbott has announced that the US Food and Drug Administration (FDA) has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, which features a flexible...
Study results demonstrate high detection accuracy for atrial fibrillation using single-lead ICD system
Results from the MATRIX study show that the high detection accuracy of DX single-lead implantable cardioverter defibrillator (ICD) systems for atrial fibrillation (AF) episodes...
Talking therapy associated with reduced risk of cardiovascular disease
Effective management of depression through psychological therapy is associated with a lower likelihood of heart disease and stroke, according to research published today in...
Medtronic mapping and ablation system shows “safety and performance” in treating AF
Medtronic have announced the 12-month findings that supported the Affera Mapping and Ablation system CE Mark, demonstrating that the Sphere-9 catheter can successfully treat...
EHRA 2023: Severe COVID-19 associated with life-threatening arrhythmia onset within six months
Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia within six months compared to their peers without...
EHRA 2023: Footballer Iker Casillas receives Gold Medal award
Spanish footballer, Iker Casillas, was awarded an European Heart Rhythm Association (EHRA) Gold Medal for services to cardiovascular health yesterday at the 2023 annual...
EHRA 2023: Extended ECG monitoring detects more arrhythmias in hypertrophic cardiomyopathy
Thirty-day electrocardiogram (ECG) monitoring in patients with hypertrophic cardiomyopathy (HCM) detects more arrhythmias than the standard 24 to 48 hours, according to late breaking...
Atrial fibrillation risk linked to excessive daytime napping
Daytime napping for 30 minutes or longer is associated with an increased likelihood of developing atrial fibrillation (AF), according to research presented at European...
Smart watches could predict higher risk of heart failure and arrhythmia
Wearable devices such as smart watches could be used to detect a higher risk of developing heart failure and irregular heart rhythms in later...
Experts update consensus on left atrial appendage closure
The Society for Cardiovascular Angiography & Interventions (SCAI) and the Heart Rhythm Society (HRS) have released an updated expert consensus statement on transcatheter left...
Health benefits of early rhythm control come with “reasonable” costs for patients with atrial...
Patients with atrial fibrillation (AF) have been said to benefit from early rhythm control therapy, which reduces cardiovascular deaths, strokes, and other adverse outcomes...
Medtronic receives CE Mark approval for Affera mapping and ablation system to treat arrhythmias
Medtronic has announced today that it has received CE Mark for the Affera mapping and ablation system, which includes the Sphere-9 catheter and the...
Brainomix technology integrated into new UK atrial fibrillation study
Brainomix has announced its involvement in a new study sponsored by the University of Liverpool (Liverpool, UK) focused on post-stroke atrial fibrillation (AF). Sites...
“First study” finds six-fold increase in bradyarrhythmia diagnosis using long-term ILR screening
A retrospective analysis of randomised clinical trials has found that one in five patients aged 70 years or older with cardiovascular risk factors are...
Basketballer Kareem Abdul-Jabbar joins campaign to raise awareness of atrial fibrillation
Kareem Abdul-Jabbar is working with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AF) and its symptoms as part of the...
First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery...
AtriCure has announced that the first patient was treated in the LeAAPS clinical trial, a prospective, randomised clinical trial to evaluate the safety and...
One-year data on CLAAS LAAO system demonstrate technical success of procedure
Conformal Medical has announced the presentation of one-year data from the company’s initial left atrial appendage occlusion (LAAO) cases with its novel CLAAS system...
Digital cardiovascular care company tenacio launches US OptiCor AF patient management system
tenacio, a company focused on digitising cardiovascular care to improve patient outcomes and reduce healthcare costs, has announced its OptiCor patient management platform is...
Atrial fibrillation does not modify treatment effect of bridging thrombolysis, study finds
An international study conducted by Leonard Yeo (National University Hospital, Singapore) and colleagues has found that the presence of atrial fibrillation does not modify...
Preclinical study outlines key features of foam-based LAA closure device
A preclinical study demonstrating key features of the foam-based left atrial appendage closure device (CLAAS, Conformal Medical) has been published in the Journal of...
Cardiac Insight’s Cardea SOLO wearable ECG system selected for Stanford Medicine study measuring AF...
Cardiac Insight, a specialist in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, has announced that researchers at...
Enrolment begins in trial to assess efficacy and safety of abelacimab in patients deemed...
Anthos Therapeutics has announced that it has enrolled the first patient in LILAC-TIMI 76, a phase 3 study to evaluate the efficacy and safety...
UK regulator approves dapagliflozin for use in heart failure across the full spectrum of...
AstraZeneca has today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin (Forxiga) in Great Britain...
Catheter ablation shown to reduce mortality and hospitalisation in patients with atrial fibrillation and...
An analysis of randomised controlled trials (RCTs) has found catheter ablation reduces mortality and heart failure hospitalisations in patients with atrial fibrillation (AF) and...
Shared decision-making tool reduces decision conflict and patient regret in use of anticoagulants for...
A recent presentation by Paul J Wang (Stanford School of Medicine, Stanford, USA) at the American Heart Association (AHA) Scientific Session 2022 conference (5-7...
Study compares risk of dementia in AF patients undergoing catheter ablation versus drug-therapy
Biosense Webster has announced the publication of data from a study comparing the risk of dementia in patients with atrial fibrillation (AF) who were...
Ablation as first-line treatment cuts AF progression compared to antiarrhythmic drugs
Ablation as a first-line treatment for atrial fibrillation (AF) disease is associated with significantly better clinical outcomes than starting with antiarrhythmic drugs.
These were the...
RELIEF clinical study to assess use of Cardioform septal occluder for migraine relief
WL Gore & Associates has announced that it is initiating the RELIEF clinical study—an investigational study to evaluate the safety and efficacy of transcatheter...
AF screening strategy “would save societal costs”
Screening to detect atrial fibrillation (AF) in older people would not only increase the chance of preventing stroke, it would also save money for...
Health economic analysis finds benefit to AF screening with Zio XT ambulatory patch
iRhythm Technologies has announced a new health economic analysis of the mSToPS study, presented at the American Heart Association (AHA) scientific sessions 2022 (5–7...
Boston begins European launch of LUX-Dx insertable cardiac monitor
Boston Scientific has announced the European launch of the LUX-Dx insertable cardiac monitor (ICM) system, a long-term diagnostic device inserted under the skin of...
Apixaban associated with lower risk of gastrointestinal bleeding in AF patients compared to other...
Use of apixaban was associated with a lower risk of gastrointestinal bleed and similar rates of ischaemic stroke or systemic embolism, intracranial haemorrhage and...
Catheter ablation of AF “increased cerebral blood flow”, observational study finds
Catheter ablation of atrial fibrillation (AF) has favourable effects on cerebral blood flow, particularly in non-paroxysmal AF, research published in JACC: Clinical Electrophysiology.
The results...
AI algorithm identifies hidden AF cases in screening study
Researchers have used artificial intelligence (AI) to evaluate patients’ electrocardiograms (ECGs) in a targeted strategy to screen for atrial fibrillation (AF). In the digitally-enabled,...
Puzzle Medical wins 2022 TCT Shark Tank innovation competition
Puzzle Medical Devices was announced as the winner of the Shark Tank innovation competition at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September,...
TCT 2022: Amulet occluder keeps pace with Watchman at three years
Long-term follow-up of patients with non-valvular atrial fibrillation (AF) receiving the Amplatzer Amulet left atrial appendage occlusion (LAAO) device have shown continued safety and...
Researchers find link between COVID-19 and new-onset AF
A study in Circulation: Arrhythmia and Electrophysiology has identified new-onset atrial fibrillation (AF) in one in 20 patients hospitalised with COVID-19.
Using data from the...
LifeTech gains medical insurance coverage for clinical trial of LAmbre LAA closure system
LifeTech has announced that a US Food and Drug Administration (FDA)-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre Plus left atrial appendage (LAA)...
Centauri pulsed electric field system gains CE mark approval
Galaxy Medical has announced that it received the CE mark for its Centauri pulsed electric field (PEF) system and launched its commercial programme.
The approval...
ESC 2022: Smartphone screening doubles AF detection rate in eBRAVE-AF
Screening for atrial fibrillation (AF) using a smartphone app more than doubled the detection and treatment rate in older people compared to routine screening,...
Recent AF diagnosis and multiple comorbidities warrants early rhythm control strategy
Patients with recently diagnosed atrial fibrillation (AF) with a high burden of comorbidities should be considered for early rhythm control to reduce cardiovascular outcomes,...
“Worrisome” rise in cardiovascular disease predicted out to 2060
Projected rates of cardiovascular risk factors and disease will increase significantly in the USA by 2060, a study published in the Journal of the...
Analysis sets out generalisability of EAST-AFNET 4 trial findings
Around 80% of patients diagnosed with atrial fibrillation (AF) in the UK population are eligible for early rhythm control, an analysis of the EAST-AFNET...
Catheter ablation “economically attractive” compared to drug therapy for AF
Catheter ablation of atrial fibrillation (AF) was economically attractive compared with drug therapy in the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial...
AF after surgery is linked to an increased risk of heart failure hospitalisation
People who develop an arrhythmia after surgery have an increased risk of subsequently being admitted to hospital with heart failure, according to a study...
Thromboembolic cerebral events ‘rare’ in patients undergoing PFA
In patients treated with pulsed field ablation (PFA) for symptomatic paroxysmal atrial fibrillation (AF), the incidence of asymptomatic thromboembolic cerebral events or lesions detected...
CONFORM pivotal trial of CLAAS system begins enrolment
Conformal Medical has announced the launch of the CONFORM pivotal trial with the enrolment of the first patients at two US sites.
The investigational device...
TVT 2022: DAPT after Watchman FLX LAAO is comparable to currently approved regimens
Dual antiplatelet therapy (DAPT) after left atrial appendage occlusion (LAAO) using the Watchman FLX (Boston Scientific) device was comparable in terms of rates of...
Abbott announces US availability of Amplatzer steerable delivery sheath for Amulet device
Abbott has announced US availability of its Amplatzer steerable delivery sheath, which is used with the company's Amplatzer Amulet left atrial appendage (LAA) occluder...
Fitbit’s PPG algorithm gains FDA clearance
Fitbit has received clearance from the US Food and Drug Administration (FDA) for a new photoplethysmography (PPG) algorithm to identify atrial fibrillation (AF). The...
EHRA 2022: GPs back routine AF screening
Screening for atrial fibrillation (AF) should be integrated into flu vaccination and cancer screening programmes, according to a survey of general practitioners (GPs) conducted...
EHRA 2022: Overweight patients at greater risk of AF recurrence
Overweight patients with atrial fibrillation (AF) are more likely to experience a return of the heart rhythm disorder after a corrective procedure than those...
EHRA 2022: Experts preach caution on “over-the-counter” heart rhythm monitoring devices
The “exponential growth” in the use of digital devices for monitoring arrhythmias has led to the development of a new international consensus document. The...
Algorithm could enhance prevention of sudden cardiac arrest
Researchers have developed a clinical algorithm that distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition.
The findings, Journal of the American...
Analysis reveals impact of kidney function on antithrombotic therapy bleeding risk
Research published in the journal BMC Medicine investigates the impact of kidney function in patients on antithrombotic therapy.
The study, a post hoc sub-group analysis...
Hospitals trial AI-backed technology to speed up arrhythmia diagnosis
Hospitals in England are trialling remote monitoring technology from iRhythm Technologies—Zio XT—which is designed to aid the detection of arrhythmias supported by artificial intelligence.
Typically...
Study shows improved AF detection using MCOT patch and implantable loop recorder
Royal Philips has announced new research evaluating mobile cardiac outpatient telemetry (MCOT) as a first-line diagnostic ambulatory monitoring solution with post-cryptogenic stroke patients.
The study...
Same-day discharge for catheter ablation of atrial fibrillation deemed safe and feasible
A recent systematic review and meta-analysis, published in the Journal of Interventional Cardiac Electrophysiology, has deemed same-day discharge following catheter ablation of atrial fibrillation...
CRT 2022: SURPASS registry shows low rate of adverse events associated with Watchman FLX
Results from a new analysis assessing real-world outcomes with the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) demonstrated a low rate of...
UK study shows lack of awareness over signs of arrhythmia
Fewer than half of UK citizens are aware of the link between arrhythmia and stroke, while around one in five people with a personal...
Robert Califf to return as US FDA commissioner
Cardiologist and researcher Robert Califf has been confirmed as the commissioner of the US Food and Drug Administration (FDA). Califf returns to the role...
Corvia atrial shunt fails to reduce heart failure events in REDUCE LAP-HF II trial
The placement of an interarterial shunt device—the Corvia atrial shunt (Corvia Medical)—did not reduce the total rate of heart failure events in a population...
Same-day discharge could become the standard strategy following LAAO
A same-day discharge strategy for left atrial appendage occlusion (LAAO) could become the standard approach for this technique, according to the authors of a...
Study shares success of complete PVI using only pulsed field ablation
A recent study has demonstrated 100% pulmonary vein isolation (PVI) using only pulsed field ablation (PFA), resulting in no PFA-related serious adverse events. This...
NICE approves KardiaMobile for AF detection in patients with suspected paroxysmal AF
The National Institute for Health and Care Excellence (NICE) has issued Medical Technologies Guidance (MTG) recommending KardiaMobile (AliveCor) as an option for detecting atrial...
AHA 2021: Fitbit shows promise for detection of AF
Results of the Fitbit Heart study, presented during a late-breaking science session at the American Heart Association’s Scientific Sessions 2021 (AHA 2021; 13–15 November;...
Patients with both atrial fibrillation and diabetes less likely to notice an irregular heartbeat
Adults with type 1 or type 2 diabetes and atrial fibrillation (AF) are less likely to notice irregular heartbeat symptoms, more likely to have...
Vektor Medical’s vMap receives FDA 510(k) clearance
Vektor Medical has announced US Food and Drug Administration (FDA) 510(k) clearance for its novel computational electrocardiogram (ECG) mapping system, vMap.
vMap is designed to...
TCT 2021: LAAC remains non-inferior to NOAC for cardiovascular events at long-term follow-up
Left atrial appendage occlusion (LAAC) remains non-inferior to non vitamin-K-antagonists (NOACs) for the prevention of major cardiovascular, neurological or bleeding events in patients with...
Non-invasive technique could detect thrombosis caused by AF
Researchers from Massachusetts General Hospital (MGH, Boston, USA) have reported the detection and characterisation of thrombosis using fibrin-targeted positron emission tomography and magnetic resonance...
CHANGE AFib to explore impact of early treatment of AF
A pragmatic clinical trial—CHANGE AFib—will determine whether early treatment with the antiarrhythmic drug dronedarone improves cardiovascular and long-term outcomes in patients presenting with first-detected...
FDA monitoring gender differences in outcomes with LAAO devices
The US Food and Drug Administration (FDA) has informed healthcare providers of recent information about the potential for differences in procedural outcomes between women...
Abbott’s Amplatzer Talisman gains FDA approval
Abbott has announced that the US Food and Drug Administration (FDA) has approved the company's Amplatzer Talisman PFO Occlusion System to treat people with...
Targeting atrial fibrosis in AF patients with low levels of disease “may help improve...
Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ablation success rates compared to PVI alone in patients with persistent...
Zoll signs agreement to acquire Itamar Medical
Zoll Medical and Itamar Medical have announced that the two companies signed a definitive agreement under which Zoll Medical will acquire all outstanding ordinary...
ESC 2021: Edoxaban shown to be noninferior to warfarin for adverse events after TAVI
Edoxaban is noninferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation (TAVI), new...
ESC 2021: Abbott’s Amulet occluder shows promise against Watchman device in AF treatment
Abbott has announced late-breaking data from the Amulet LAA Occluder IDE trial, a multicentre, head-to-head study comparing the company's Amplatzer Amulet left atrial appendage...
Night shift work may be linked to increased risk of AF
People who work night shifts are at increased risk of developing atrial fibrillation (AF), according to research published in the European Heart Journal.
The study...
Abbott’s Amplatzer Amulet gains US FDA approval
Abbott has announced that the US Food and Drug Administration (FDA) has approved the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people...
Caption Health gains NTAP authorisation from CMS for AI-guided ultrasound platform
Caption Health has announced that the Centers for Medicare and Medicaid Services (CMS) have approved new technology add-on payments (NTAP) for the Caption Guidance...
Exploring the potential of remote atrial fibrillation diagnosis through digital technology
The challenge of rapid detection and diagnosis of atrial fibrillation (AF) has been made even harder with the onset of the COVID-19 pandemic, and...
HRS 2021: Early rhythm control benefits AF patients with heart failure
Rhythm control therapy offers a clinical benefit when initiated within one year of a diagnosis of atrial fibrillation (AF) in patients with signs or...
HRS 2021: CABANA analysis points to economic case for catheter ablation
A new analysis of the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation) suggests that catheter ablation offers positive economic outcomes compared...
Cardiac rehabilitation reduces rehospitalisation, death in ICD recipients
People who made even small increases in their daily physical activity levels after receiving an implantable cardioverter defibrillator (ICD) experienced fewer incidences of hospitalisation...
Research highlights AF risk factors for HCM patients
The authors of research published in JACC: Clinical Electrophysiology claim that their findings will help physicians to identify, treat and prevent atrial fibrillation (AF)...
CABANA trial shows favourable results for catheter ablation among ethnic minority patients
Among racial or ethnic minority patients enrolled in the North American cohort of the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation)...
AHA statement on AF and HFrEF positive for catheter ablation
The American Heart Association (AHA) has this week issued a scientific statement on the management of atrial fibrillation (AF) in patients with heart failure...
Vaccination centre screening campaign reports success at “opportunistic” AF detection
A campaign by Arrhythmia Alliance to DETECT atrial fibrillation (AF)—the most common type of arrhythmia—found that 6% of people aged 65 or older attending...
Abbott’s Amplatzer steerable delivery sheath gains EU and Canadian approvals
Abbott has announced it has received CE mark and Health Canada approval for its Amplatzer steerable delivery sheath, which is used with the company's...
Medtronic stops sale of its HVAD system
Medtronic is stopping the distribution and sale of the Medtronic HVAD system. This morning, the company notified physicians to cease new implants of the...
Wearables study shows physical activity reduces AF risk
Physical activity that conforms to medical and health association guidelines is associated with a lower risk of atrial fibrillation (AF) and stroke, according to...
Single-shot pulsed-field ablation yields “excellent” PVI durability
Pulmonary vein isolation (PVI) with a “single-shot” pulsed-field ablation (PFA) catheter results in excellent PVI durability and acceptable safety with a low one-year rate...
EHRA 2021: Efforts should be made to increase participation in atrial fibrillation screening
Further efforts should be made to increase participation in atrial fibrillation (AF) screening—particularly in elderly populations, where systematic screening for AF can help to...
Smartphone ECG screening app aided detection of AF among American Indians
A smartphone-based electrocardiogram (ECG) screening accurately detected previously unknown atrial fibrillation (AF) in American Indians, and more than half who were diagnosed were younger...
EHRA 2021: Diabetic patients could be screened for AF during foot assessments
Atrial fibrillation (AF) could be detected during annual foot assessments in patients with diabetes, according to research presented today at the European Heart Rhythm...
Putting the patient at the centre of the AF treatment strategy
This article was sponsored by Biosense Webster
Putting the patient at the centre of the discussion is vital to setting the right strategy for the...
Oxford study to assess smart devices for AF detection
A project at Oxford University Hospitals NHS Foundation Trust (Oxford, UK) to test how effective smart devices are at detecting heart rhythm problems has...
MultiPulse therapy “shows promise” in the treatment of AF
Cardialen has announced the publication of a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology investigating its low-voltage MultiPulse...
Charity targets vaccine centres for opportunistic AF screening campaign
AF Association has launched an opportunistic screening programme to DETECT atrial fibrillation (AF) at COVID-19 vaccination clinics across the UK. The charity has created...
DOACs show better safety and effectiveness versus warfarin in patients with valvular AF
Patients with valvular atrial fibrillation (AF) who were new users of direct oral anticoagulants (DOACs) were at lower risk for ischaemic stroke or systemic...
US FDA grants Breakthrough Device Designation for AF ECG analysis platform
Tempus has announced that the US Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG analysis platform. The...
Daiichi Sankyo leads partnership to improve access to at-home AF diagnostics
Daiichi Sankyo has announced that it has entered into a collaborative agreement with three technology partners—FibriCheck, neoHealthTech and Capitol Medicare—to improve timely detection and...
Mavacamten granted US FDA new drug application
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for mavacamten, an investigational,...
Higher procedural volume linked to better outcomes for LAAO
Higher procedural volume is associated with better outcomes for percutaneous left atrial appendage occlusion (LAAO) procedures, research published online in JACC: Cardiovascular Interventions has...
Five-year results of Gore REDUCE clinical study published
Five-year follow-up results from the Gore REDUCE study, assessing the Gore Cardioform or Helex septal occluder versus antiplatelet therapy in long-term recurrent stroke prevention,...
ACC.21 late-breaking clinical trial programme announced
The American College of Cardiology (ACC) has announced a number of the late-breaking clinical trials to be presented at its 70th annual scientific session...
SCREEN-AF study results published in JAMA Cardiology
iRhythm Technologies has announced the results of the SCREEN-AF study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital...
“Strong evidence” of a causal link between high blood pressure and AF
A study published in the European Journal of Preventive Cardiology provides “strong evidence” of a causal relationship between elevated blood pressure and atrial fibrillation...
B-Secur receives FDA clearance for its HeartKey EKG/ECG technology
B-Secur has announced that it has received US Food and Drug Administration (FDA) 510(K) clearance for its HeartKey software library.
B-Secur’s HeartKey is a suite...
AF Symposium 2021: HARTCAP-AF supports hybrid over catheter ablation
Hybrid ablation, a procedure which involves “attacking” the atrial substrate from the epicardium and endocardium, has been shown to result in significantly higher freedom...
Cardialen awarded US$2.8 million grant for study of low-energy cardioversion in AF
Cardialen has been awarded a US$2.8 million National Institutes of Health (NIH) phase II SBIR grant to further the clinical study of low-energy cardioversion...
Blood pressure bracelet “offers greater insight” into hypertension
Following the announcement of CE mark approval for the Aktiia cuffless blood pressure monitor bracelet, Gregoire Wuerzner (Lausanne University Hospital and University of Lausanne,...
InCarda Therapeutics announces enrolment of first US patient in phase 2 INSTANT trial
InCarda Therapeutics has announced dosing of the first US patient in the company’s multinational INSTANT Phase 2 clinical trial of InRhythm (flecainide for inhalation)...
Activating patient engagement to evolve AF care
Patient engagement is key to optimising outcomes in the treatment of atrial fibrillation (AF) argues Elana Arbelo (Consultant Cardiac Electrophysiologist and Community Cardiologist, Hospital...
Wearables offer “great potential” in AF screening but physicians cautious over mass use
Consumer wearables offer a great potential for the screening of atrial fibrillation (AF), however two thirds of healthcare professionals admit to concerns over mass...
ACC recommends against “triple therapy” in AF patients
The American College of Cardiology (ACC) has issued guidance recommending against triple antithrombotic therapy in patients with atrial fibrillation (AF), due to its increased...
CardioFocus announces 10,000-patient milestone for HeartLight ablation system
CardioFocus has announced that more than 10,000 patients worldwide have been treated with the HeartLight endoscopic ablation system.
The HeartLight system is a catheter ablation...
Zio XT cardiac monitor recommended for NICE guideline adoption
iRhythm Technologies has announced it is the first technology to pass through a new digital health tech pilot, resulting in a successful recommendation for...
AHA 2020: Active AF screening associated with significant improvement in clinical outcomes at three...
Three-year clinical outcomes of the mHealth Screening to Prevent Strokes—mSToPS—study evaluating silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using Zio, the...
AHA 2020: AF detected more often in high risk patients recovering from cardiac surgery
Atrial fibrillation (AF) was detected up to 10 times more frequently in high risk patients recovering from heart surgery who wore a continuous cardiac...
AHA 2020: Rivaroxaban may be comparable to warfarin for bioprosthetic mitral valves, AF
The primary results from the RIVER Trial—Rivaroxaban for Valvular Heart disease and Atrial Fibrillation—show that rivaroxaban is comparable to warfarin for patients with bioprosthetic...
Append Medical completes transcatheter implant-free LAA occlusion procedures
Append Medical, developer of the Appligator implant-free left atrial appendage (LAA) occlusion device, today announced completion of its first pre-clinical chronic procedures. The procedures...
American Heart Association issues call for action on structural racism in cardiovascular care
Structural racism is a major cause of poor health and premature death from heart disease and stroke, according to a presidential advisory issued today...
Boston Scientific initiates CHAMPION-AF trial of Watchman FLX
Boston Scientific has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the Watchman FLX left atrial appendage closure (LAAC) device...
High-risk surgery patients vulnerable to cardiovascular diseases
One in five high-risk patients undergoing major non-cardiac surgery will develop one or more heart complications within a year, according to research published today...
Development of AF after CABG linked to higher risk of cerebrovascular accidents at 10...
Patients with postoperative atrial fibrillation (AF) after coronary artery bypass graft (CABG) surgery are at a higher risk of cerebrovascular accidents (CVAs) up to...
Catheter ablation linked to lower incidence of dementia in AF patients
People with atrial fibrillation (AF) have a reduced risk of dementia if they undergo catheter ablation to restore the normal rhythm of their heart,...
US FDA approves Biosense Webster’s Thermocool Smarttouch SF ablation catheter
Johnson & Johnson Medical Devices Companies has announced the US Food and Drug Administration (FDA) approval of Biosense Webster’s Thermocool Smarttouch SF ablation catheter...
Study finds over 2,000 excess cardiovascular deaths in England and Wales during pandemic
Research has identified 2,085 excess deaths in England and Wales linked to cardiovascular disease during the peak of the COVID-19 pandemic. On average, that...
VivaLNK wearable ECG to be used in AF biomarkers study
VivaLNK has announced that the University of California, San Francisco (UCSF) (San Francisco, USA), will be utilising its continuous wearable electrocardiogram (ECG) sensor for...
Redesigning pathways to incorporate innovative technologies into primary care
Yassir Javaid (Northampton, UK) discusses the use of cloud-based technologies and machine learning to improve the treatment and detection of arrhythmias.
What potential is there...
Philips launches latest version of its Azurion imaging platform
Royal Philips has announced the next-generation of its Azurion image-guided therapy platform, designed to improve the quality and efficiency of interventional procedures. The Azurion...
ESC 2020 Congress: IMPACT-AFib finds no statistical difference in anticoagulant usage
A study investigating an educational intervention aimed at increasing the use of oral anticoagulants for stroke prevention among atrial fibrillation (AF) patients, found that...
ESC 2020 Congress: Digoxin found to be favourable in rate control for permanent AF...
Digoxin should be considered as a first-line approach for rate control in patients with permanent atrial fibrillation (AF). This was the conclusion of the...
ESC 2020 Congress: AF associated with long-term mortality in primary PCI patients regardless of...
Atrial fibrillation (AF) is associated with long-term mortality in patients undergoing primary percutaneous coronary intervention (PCI), irrespective of left ventricular (LV) function, a study...
ESC 2020 Congress: Daiichi Sankyo announces results from ETNA-AF studies
Daiichi Sankyo Europe has announced one-year results of four sub-analyses from the European and global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients...
ESC Congress 2020: EAST-AFNET 4 finds early rhythm control improves AF outcomes
Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy, according to results of the EAST-AFNET 4 trial presented in a Hot...
ESC 2020 Congress: STOP AF First finds cryoballoon ablation safer than drug treatment for...
Cryoballoon catheter ablation as a first line treatment for paroxysmal atrial fibrillation (AF) was found to be safer and more effective than anti arrhythmic...
ESC Congress 2020: Guidelines push individualised approach to AF
Patients with arrhythmia should choose the treatment plan with their health professionals, according to European Society of Cardiology (ESC) guidelines published online today in...
Low rates of bleeding and mortality reported in one-year results of ETNA-AF trial
Daiichi Sankyo Europe has announced the publication of one-year follow-up results from the ongoing ETNA-AF-Europe (Edoxaban Treatment in routiNe clinical prActice for patients with...
First procedures performed in the USA using Watchman FLX LAAC device
Physicians at the Texas Cardiac Arrhythmia Institute (TCAI) at St David's Medical Center in Austin and Los Robles Health System in Thousand Oaks, became...
Conformal Medical secures funding to support CLAAS device trial
Conformal Medical, a medical device company focused on reducing stroke in patients with atrial fibrillation (AF), today announced it has secured US$85 million in...
Prompt diagnosis “vital” in effective AF management
Dhiraj Gupta, consultant cardiologist and electrophysiologist at Liverpool Heart and Chest Hospital, (Liverpool, UK) discusses the current burden of atrial fibrillation (AF) on healthcare...
Next-generation Watchman LAAC device gains US FDA approval
Boston Scientific has received US Food and Drug Administration (FDA) approval for the Watchman FLX left atrial appendage closure (LAAC) device. The device is...
Study shows LAAO reduces major bleeding and mortality compared with NOACs in high-risk AF...
Jens Erik Nielsen-Kudsk (Aarhus, Denmark) speaks to Cardiovascular News about a propensity score-matched study which examined left atrial appendage occlusion (LAAO) compared with novel...
American Heart Association appoints Mitchell Elkind as president
The American Heart Association (AHA) has named Mitchell SV Elkind as president of the organisation for its 2020–2021 fiscal year, which began on 1...
PCR e-Course 2020: Roll-in trial finds high device success rate for Amplatzer Amulet occluder
Left atrial appendage occlusion (LAAO) using the Amplatzer Amulet (Abbott) device has a high implant success rate and a low procedural complication rate in...
Boston Scientific gets FDA 510(k) clearance for Lux-Dx ICM
Boston Scientific has received US Food and Drug Administration (FDA) 510(k) clearance for the Lux-Dx insertable cardiac monitor (ICM) system, a new, long-term diagnostic...
PCR e-Course 2020: Left atrial appendage occlusion improves clinical outcomes versus NOACs in high...
Left atrial appendage occlusion (LAAO) improves clinical outcomes including ischaemic stroke, major bleeding and all-cause mortality, in atrial fibrillation (AF) patients with a high...
HRS 2020 Science: Packer assesses CABANA’s legacy
As part of this year’s HRS 2020 Science virtual event Douglas L Packer (Mayo Clinic, Rochester, USA) delivered the 2020 Eric N Prystowsky lecture...
Societies publish consensus statement on risk assessment in arrhythmias
Global cardiac health societies have collaborated on a consensus statement on the diagnosis of arrhythmias, designed to provide physicians with practical proposals to improve...
British Heart Foundation calls for urgent resumption of routine services for heart and circulatory...
The British Heart Foundation (BHF) is calling on the Government and the NHS to urgently address the immediate needs of heart and circulatory patients...
AI-based ECG analysis reduces false positives in AF detection
Cardiologs, in partnership with the Valley Health System, has announced the results of a clinical study that found the Cardiologs AI-based ECG analysis solution...
COVID-19: Anticoagulants may improve survival among hospitalised COVID patients
Corresponding author Valentin Fuster (Mount Sinai Heart, New York, USA) and colleagues report in the Journal of the American College of Cardiology that hospitalised...
Boston Scientific announces positive PINNACLE FLX study results
Boston Scientific has announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX Left...
Results of PULSED AF trial presented at HRS 2020 Science
Initial results of the PULSED AF trial, the first-in-human results for paroxysmal or persistent atrial fibrillation (AF) treated with pulsed field ablation (PFA) were...
Heart Rhythm Society launches white paper on AF centres of excellence
The Heart Rhythm Society (HRS) has released a white paper announcing the rationale and core components for Atrial Fibrillation (AF) centres of excellence (CoE),...
Fitbit to enrol patients in AF detection study
Fitbit has today launched the Fitbit Heart Study, its first large-scale, virtual study to validate the use of its wearable technology to identify episodes...
Wearable necklace-ECG can detect abnormal heart rhythm
A necklace that detects abnormal heart rhythm will be showcased for the first time on EHRA Essentials 4 You, a scientific platform of the...
Wearable necklace-ECG can detect abnormal heart rhythm
A necklace that detects abnormal heart rhythm will be showcased for the first time on EHRA Essentials 4 You, a scientific platform of the...
Same-day discharge “feasible for majority of AF ablation patients”
Same-day discharge after atrial fibrillation (AF) ablation is feasible for the majority of patients when a standardised protocol is used, findings of a multicentre cohort study, published in the Journal of the American...
Cardiac Insight launches Heart@Home ECG test kit
Cardiac Insight has announced the launch of the Heart@Home electrocardiogram (ECG) test kit to address new telehealth demands placed on cardiology practices by the...
Virtual ACC: Largest left atrial appendage occlusion registry finds Watchman acute safety data “very...
Data from the National Cardiovascular Data Registry (NCDR) Left Atrial Appendage Occlusion (LAAO) Registry, which enrolled more than 38,000 patients implanted percutaneously with the...
AHA commits US$2.5 million for fast-tracked COVID-19 heart and brain research
The American Heart Association (AHA) has committed US$2.5 million to research efforts to better understand the novel coronavirus, COVID-19, and its interaction with the...
Algorithms can identify rate of OAC prescription for AF in emergency departments
Researchers have derived several algorithms to identify emergency department (ED) oral anticoagulant prescriptions for patients with atrial fibrillation (AF) in a large health dataset....
Leadless pacing shows high rate of success at six months
Almost 70% of patients treated with a leadless left ventricular (LV) endocardial pacing system had a favourable clinical response at six months, a post-market...
Novel device “safely obliterates” left atrial appendage with minimal amount left behind
The novel left atrial appendage (LAA) closure device Appligator (Append Medical) was a finalist in the 2019 ICI Innovation Award Competition (Innovation in Cardiovascular...
Focus on the Zio Patch wearable sensor in diagnosis of cardiac arrhythmias
James Teo was the chief investigator in the EPACS clinical trial, testing the performance of the Zio Patch (iRhythm Technologies) wearable biosensor. He outlines...
Novel lattice tip catheter safe, feasible, and durable in RF ablation
Rapid high-current, temperature-controlled point-by-point pulmonary vein isolation (PVI) and linear ablation has been shown to be clinically feasible and safe in a first-in-human study...
Append Medical shares clinical proof-of-concept results for internal sealing of LAA
Append Medical, developer of the Appligator, a novel left atrial appendage (LAA) closure device to minimise stroke risk in atrial fibrillation (AF) patients, and...
Abbott receives CE mark approval for Gallant ICD and CRT-D devices
Abbott has announced that it has received CE mark approval for the Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices.
The...
AF Symposium 2020: Use-as-needed NOAC strategy is safe and effective for selected AF patients
Speaking today at the AF Symposium (23–25 January, Washington, DC, USA), Francis Marchlinski (Hospital of the University of Pennsylvania, Philadelphia, USA) reported that selected...
Biotronik announces Japanese launch of injectable cardiac monitor
Biotronik has announced the market release of its injectable cardiac monitor (ICM), BioMonitor III in Japan. The device is designed to help patients with...
Eric N Prystowsky
Eric N Prystowsky (director of the Cardiac Arrhythmia Service at St Vincent Hospital, Indianapolis, and a consulting professor of medicine at Duke University Medical...
NICE recommends use of Reveal LINQ implantable cardiac monitor
The UK National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of the Reveal LINQ (Medtronic) implantable cardiac...
European trial data ‘reinforce’ safety profile and efficacy of Lixiana
Daiichi Sankyo Europe has announced outcomes from an observational study in mainly caucasian atrial fibrillation (AF) patients being treated with the anti-coagulation drug edoxaban...
Biosense Webster launches initiatives to tackle atrial fibrillation
Biosense Webster, a Division of Johnson & Johnson, has reaffirmed its commitment to tackling atrial fibrillation (AF) by launching two major initiatives to coincide...
Apple Heart study finds low rates of AF notification, and high level of agreement...
Final results from the Apple Heart study demonstrate a low probability of receiving an irregular pulse notification. It also found that 34% of those...
Global AF Aware Week 2019 begins on 18 November
Monday 18 November marks the start of Global AF Aware Week 2019, launched by the AF Association. The annual awareness week is dedicated to...
Study suggests routine use of AI-based machine learning algorithms could increase detection of undiagnosed...
A joint press release from Bristol Myers Squibb and Pfizer has highlighted the findings of an artificial intelligence (AI)-based machine learning (ML) technique that...
Medtronic releases MARVEL 2 data on leadless pacing in AV block
Medtronic has announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study. A press release from the company says that...
Low bleeding and cardiovascular events in elderly NVAF patients using edoxaban, European results show
Daiichi Sankyo has announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly, treated with edoxaban (Lixiana)....
iRhythm launches Zio patch in the UK
iRhythm Technologies has launched its Zio service in the UK to support the identification and clinical diagnoses of cardiac arrhythmias such as atrial fibrillation...
US FDA approves Farxiga for reduction in risk of heart failure hospitalisations in type...
The US Food and Drug Administration (FDA) has approved Farxiga (dapaglifozin, AstraZeneca) to reduce the risk of hospitalisation for heart failure in adults with...
President of Venice Arrhythmias discusses current challenges in atrial fibrillation management
Antonio Raviele (Venice, Italy), the president of Venice Arrhythmias 2019 (3–5 October; Venice, Italy), talks to BLearning Cardio about some of the current challenges in atrial fibrillation (AF)...
Orchestra BioMed announces positive data for its BackBeat Cardiac Neuromodulation Therapy
Orchestra BioMed, a biomedical innovation company, announced results from its MODERATO II double-blind, randomised study of BackBeat Cardiac Neuromodulation Therapy (CNT). In a press...
TCT 2019: Apixaban plus a P2Y12 inhibitor is the optimal strategy for AF with...
A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at the Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019; 25–29 September,...
Individualised home-based education dramatically decreases atrial fibrillation-related hospitalisations and other cardiovascular admissions
Personalised education delivered in a home setting significantly reduces hospitalisations in patients with atrial fibrillation (AF). This was among the findings of the HELP-AF...
iRhythm and Verily to collaborate on health management solutions for atrial fibrillation patients
iRhythm Technologies has announced a collaboration with Verily to develop solutions aimed at improving the screening, diagnosis, and management of patients with atrial fibrillation...
ESC 2019: Catheter ablation may be up to 10 times more effective than drug...
Results from the Atrial fibrillation progression trial (ATTEST) were presented on 31 August at the European Society of Cardiology (ESC) Congress 2019 in Paris,...
ESC 2019: Left atrial appendage closure is non-inferior to NOACS for preventing neurological events
At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Pavel Osmancik (Charles University and University Hospital Kralovske Vinohrady, Prague,...
ESC 2019: Study suggests increased use of DOACs in AF leads to lower healthcare...
A four-year Italian study of oral anticoagulant (OAC) use in patients with atrial fibrillation (AF) has shown that as prescription rates increased healthcare costs...
ESC 2019: Guidelines on supraventricular tachycardias underline pivotal role of catheter ablation
The European Society of Cardiology (ESC) unveiled guidelines for treatment of supraventricular tachycardia (SVT) on the opening day of its Congress (ESC 2019; 31...
Cardiovascular risk for heavy smokers who quit swiftly decreases but may remain high for...
A retrospective analysis of data from the Framingham Heart Study has determined that, although heavy smokers have a significantly decreased risk of cardiovascular disease...
ZOLL Medical completes acquisition of Cardiac Science
ZOLL Medical has confirmed that it has completed the previously announced acquisition of Cardiac Science Corporation, a leading provider of automated external defibrillators (AEDs), related services,...
SENSE data show DX system is equivalent to dual-chamber ICDs and superior to single-chamber...
Biotronik has announced the publication of the SENSE trial results in the Journal of Cardiovascular Electrophysiology, proving Biotronik's DX system is equivalent to dual-chamber...
SentreHeart announces initial clinical use of the Lariat with EpiRail procedure for LAA exclusion
SentreHeart recently announced it has successfully completed nine first-in-human procedures utilising the Lariat with EpiRail at John Paul II hospital in Krakow, Poland. The...
Deep learning AI may identify atrial fibrillation from a normal rhythm ECG
An artificial intelligence (AI) model has been found to identify patients with intermittent atrial fibrillation even when performed during normal rhythm using a quick...
Acutus Medical announces publication of AcQMap study results
Acutus Medical has announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology. The study demonstrated 73% single-procedure freedom from atrial...
New heart disease prevention guidelines focus on lifestyle changes and chronic disease management
The American College of Cardiology/American Heart Association (ACC/AHA) recently published new primary prevention of heart disease guidelines. The guidelines focus on traditional recommendations for...
Biotronik receives FDA clearance on BioMonitor III
Biotronik has announced FDA clearance of the BioMonitor III injectable cardiac monitor (ICM). BioMonitor III is designed to document suspected arrhythmia or unexplained syncope...
Medtronic announces global registry of HVAD thoracotomy implants
Medtronic has announced plans for a global registry of its HeartWare HVAD System, following the release of two-year outcomes from the LATERAL clinical trial....
Pooled analysis shows LAAC is cheaper than drug therapy for AF
A pooled analysis of five-year data from the PROTECT AF and PREVAIL trials has shown left atrial appendage closure (LAAC) to be cost‐effective, and...
Diagnosing AF with ICMs leads to short- and long-term changes in patient care
Using insertable cardiac monitors (ICMs) to identify atrial fibrillation (AF) in a population at high risk for stroke guides both immediate and long-term patient...
New Liverpool Centre for Cardiovascular Science established
The Liverpool Centre for Cardiovascular Science, an alliance between academia and the NHS, was established to advance cardiovascular and stroke research and innovation locally,...
White paper from Heart Rhythm Society suggests Afib treatment has reached a “turning point”
The Heart Rhythm Society has published a white paper looking at the consequences of oral anticoagulants for managing stroke risk in atrial fibrillation which...
HRS 2019: Ear clip uses neurostimulation to effectively reduce AFib burden
A trial evaluating Parasym’s neurostimulation technology shows that an ear-clip-like device can help reduce atrial fibrillation burden. The results were presented at the Heart...
Low rates of device-related thrombus found with Amplatzer Amulet occlusion device
Device-related thrombus (DRT) following left atrial appendage occlusion (LAAO) with the Amplatzer Amulet device (Abbott) was “infrequently” observed according to a report published in...
A cardiologist’s clinical experience with BIOTRONIK’s Acticor/Rivacor* ICDs and CRT-Ds
This advertorial has been sponsored by BIOTRONIK
Dr. Victor Sanfins is a cardiologist at Hospital da Senkora da Oliveira in Guimarães, Portugal, and a specialist...
US physicians now treating patients with Biotronik’s Acticor DX devices
Biotronik recently announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Leading electrophysiologists throughout the USA are...
Acutus Medical’s new contact mapping software receives CE mark
Acutus Medical recently announced CE mark approval for AcQMap contact mapping software, offering expanded functionality that provides physicians with more options to inform individualised...
Phased RFA for AF shows efficacy and quality of life improvements
Phased radiofrequency (RF) ablation using the PVAC GOLD catheter for pulmonary vein isolation in paroxysmal and persistent atrial fibrillation (AF) has demonstrated good outcomes for...
Eliminate AF shows low thromboembolic and bleeding events with edoxaban
Uninterrupted anticoagulation with edoxaban (Lixiana, Daiichi Sankyo) resulted in low rates of thromboembolic and bleeding events in patients with atrial fibrillation undergoing catheter ablation,...
CABANA finds reduced AF and better quality of life after ablation but no reduction...
Catheter ablation for atrial fibrillation leads to a reduction in atrial fibrillation, better quality of life and lower hospitalisations than medical therapy, but does...
Is CABANA a positive or negative trial?
Several treatment options are available for atrial fibrillation (AF), including pharmacological rate or rhythm control, and catheter or surgical ablation. However, consensus as to...
CE mark for Watchman FLX left atrial appendage closure device
Boston Scientific announced it has received CE mark and initiated a limited market release of the next generation Watchman FLX left atrial appendage closure...
Mapping dynamic patterns during atrial fibrillation can produce higher success rates
In a late breaking session at the 2019 AF Symposium in Boston, USA (24–26 January), it was announced that a dipole density (DD) mapping...
More than 40% of patients with a history of atrial fibrillation attend the emergency...
Patients with a previous diagnosis of atrial fibrillation who were assessed as attending the emergency department inappropriately did so because of fear, or as...
Combining practical and scientific learning to meet educational needs at Europe’s largest atrial fibrillation...
Sabine Ernst and Mattias Duytschaever are both consultant cardiologists and scientific committee members of the practical and scientific faculty of the Atrial Fibrillation Symposium,...
Patients with atrial fibrillation who are frail or have cognitive impairment are less likely...
Malini Madhavan (Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA) and others reported the results of a study in American Heart Journal that found...
Top 10 takeaways – the need to increase focus and awareness of atrial fibrillation
A new report from Biosense Webster sets out the scale and impact of atrial fibrillation (AF) across Europe and calls for greater awareness and...
New AHA treatment guidelines for use of blood thinners with atrial fibrillation
A newer type of blood-thinning medications, non-vitamin K oral anticoagulants (NOACs), is now recommended as the preferred alternative to warfarin for reducing the risk...
Editors-in-chief of major cardiovascular journals claim medical misinformation puts “lives at stake”
The editors-in-chief of major cardiovascular journals—of both US and European societies—have come together to “sound the alarm” about the dangers of medical misinformation that...
New option available for physicians treating patients with atrial fibrillation
Approval has been granted for Abbot’s TactiCath Contact Force Ablation Catheter, Sensor Enabled, which is helping more physicians integrate ablation with 3D mapping to...
Bardy Diagnostics achieves milestone of 40,000 patients monitored by the Carnation Ambulatory Monitor
It has been announced that Bardy Diagnostics has monitored over 40,000 patients driven by rapid adoption of the Carnation Ambulatory Monitor (CAM), the world's...
First patient treated in TERMINATE AF clinical trial
The first patient has been treated in the TERMINATE AF trial (Medtronic). This is a multi-centre study evaluating two surgical ablation devices—the Cardioblate irrigated...
AHA 2018: Computerised-decision support has the potential to be a “powerful tool” for preventing...
Data presented at the 2018 American Heart Association (AHA) scientific session scientific sessions (10–12 November, Chicago, USA) indicate that the use of alert-based computerised-decision...
Tim Betts
For Tim Betts, a career in medicine was a natural choice. After graduating he knew he wanted to be a cardiologist and, with a...
New report on the burden of AF in Europe released
During AF Association Global AF Aware Week, Biosense Webster EMEA has published a report that uncovers the growing burden of atrial fibrillation (AF) on...
Migraines that affect vision may increase risk of irregular heartbeat
People who experience migraine with visual aura may have an increased risk of atrial fibrillation, according to a study published in the online issue...
US FDA approve HeartMate 3 heart pump advanced heart failure patients not eligible for...
The HeartMate 3 left ventricular assist device has received US FDA approval as a destination therapy for people living with advanced heart failure. With...
Atrial fibrillation related to PFO closure occurs early and is transient
A new meta-analysis of patients undergoing percutaneous closure of patent foramen ovale (PFO) after cryptogenic shock supports previous studies that indicate PFO closure is...
Case report: Mapping a complex macroreentrant atrial arrhythmia in congenital heart disease after surgical...
This article has been sponsored by Abbott
Case description
A 31 year-old female with tricuspid atresia and normally related great vessels who underwent an atriopulmonary Fontan...
Patients with new-onset atrial fibrillation after TAVI have highest risk of complications
Amit N Vora (Duke University Medical Center/the Duke Clinical Research Institute, Durham, USA) and others report in in JACC: Cardiovascular Interventions that patients who...
CRT patients undergoing lead extraction are at no higher risk than non-CRT patients
Transvenous lead extraction in cardiac resynchronisation therapy (CRT) patients is not associated with increased 30-day mortality vs. non-CRT patients. The study found that age,...
Four out of 10 patients with atrial fibrillation have unknown brain damage
Four out of ten patients with atrial fibrillation but no history of stroke or transient ischaemic attack have previously unknown brain damage, according to...
Simultaneous TAVI and left atrial appendage closure is feasible
Thomas S Gilhofer (University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland) and others report in Structural Heart that a combined procedure...
European Society of Cardiology Congress: Cardioskin launched
WeHealth, by Servier, has launched Cardioskin—a connected solution that is designed to function as an ambulatory wearable 15-lead ECG—at the 2018 European Society of...
Novel Ultraseal device is a feasible option for left atrial appendage closure
A feasibility study of a novel left atrial appendage device (Ultraseal, Cardia) indicates that the device is associated with a high rate of procedural...
Re-evaluate use of anticoagulation in patients with atrial flutter
A new study, published in JAMA Network Open, indicates that patients with atrial flutter have a lower incidence of stroke than patients with atrial...
The rise of smartphones and wearables for AF detection: WATCH-AF and DETECT-AF pro
How to best combine optimal screening and diagnosis for atrial fibrillation (AF) has long been a challenge. At European Heart Rhythm Association Congress (EHRA;...
Boston Scientific to buy cerebral protection system company
Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system. The device is used...
Thoracoscopic ablation and left atrial appendage excision found to be superior to catheter ablation...
Symptomatic atrial fibrillation (AF) patients with previous failed catheter ablation or structural changes associated with higher recurrence of AF could benefit from thoracoscopic ablation...
Continuous homebased ECG monitoring results in a significantly higher rate of AF diagnosis
The mHealth Screening To Prevent Strokes (mSToPS) randomised clinical trial showed that home-based wearable electrocardiogram (ECG) sensor patch monitoring, compared with delayed monitoring, resulted in...
How gender impacts pathophysiology treatment of cardiac arrhythmia
Differences between men and women mean that outcomes after cardiac events can differ between the sexes. Cecilia Linde writes in Cardiac Rhythm News about...
HeartWare HVAD system receives US FDA approval
Medtronic has received United States Food and Drug Administration (FDA) approval for a less-invasive implant approach of its HVAD System, a left ventricular assist...
LVAD technology improves, providing better, longer-term outcomes
This article was sponsored by Abbott.
Left ventricular assist devices (LVAD) are mechanical pumps that are implanted inside a person's chest to help their weakened...
COMPASS trial suggests that combination of rivaroxaban and aspirin lowers the incidence of major...
By Hannah Woolley
Findings from the Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) trial suggest that the...
CABANA trial provides important new data on clinical and quality of life effects of...
Catheter ablation for atrial fibrillation (AF) produced no significant improvement in death, disabling stroke, serious bleeding, or cardiac arrest but did reduce death or...
More than US$28 million awarded for new atrial fibrillation research centres to improve patient...
The American Heart Association has announced research grants totalling more than US$28 million to the scientific teams that will create a new research network...
Zenicor selected as supplier to the world’s largest screening programme for atrial fibrillation
Zenicor Medical Systems AB has been selected as sole supplier for a screening programme in the UK for atrial fibrillation. The screening programme is...
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and...
Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 (Anticoagulation using the direct factor...
Point-of-care testing of coagulation in patients treated with edoxaban
The first systematic evaluation of coagulation point-of-care testing in edoxaban treated patients has been carried out. The results were presented by Florian Härtig, University...
Octreotide enables left atrial appendage closure in AF patients with GI bleeding
Octreotide therapy has the potential to offer atrial fibrillation (AF) patients with arteriovenous malformations (AVM) related gastrointestinal (GI) bleeding another treatment option. It is...
Luigi Di Biase
Luigi Di Biase is a prominent electrophysiologist, section head of Electrophysiology, director of Arrhythmia Services, and professor of Medicine (Cardiology) at the Albert Einstein...
Cardiac Rhythm News Issue 41 – May 2018 EU edition
Highlights:
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and may have a positive effect on cognitive function
Stroke...
Cardiac Rhythm News Issue 41 – May 2018 US edition
Highlights:
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and may have a positive effect on cognitive function
Stroke...
Late-breaking presentation at Heart Rhythm 2018 shows potential for more patients to benefit from...
An investigational algorithm, utilising the accelerometer signal in the Micra Transcatheter Pacing System (TPS) (Medtronic) may restore AV synchrony, improving cardiac function in patients...
How much should we screen?
At the AF Symposium (Orlando, USA) John Camm, St George’s University of London and Imperial College, London, UK, looked at the current status of...
Factor XI inhibitors: a new class of anticoagulants that may reduce the risk of...
More patients than ever before are being given NOACs due to their relative stability and safety, but the risk of gastrointestinal bleeding with NOACs...
Nassir Marrouche
Nassir Marrouche is a prominent electrophysiologist, executive director of the Comprehensive Arrhythmia Research and Management (CARMA) Centre at the University of Utah in Salt...
Brain MRI scans can inform the choice between OACs and LAA closure for non-valvular...
M Edip Gurol is a stroke neurologist with particular expertise in the care of patients at high risk for ischaemic (blockage type) strokes and...
New analyses show that AdaptivCRT algorithm reduces AF episodes in patients
Two real-world analyses featuring the AdaptivCRT algorithm reinforce that its use is linked to a reduction in atrial fibrillation (AF) episodes, as well as...
Interim results from ongoing ANNEXA-4 study of Factor Xa inhibitor reversal agent announced
Interim data from 228 patients (of which 132 were adjudicated for efficacy) showed that AndexXa rapidly and significantly reversed anti-Factor Xa activity (the anticoagulant...
Zio by iRhythm shown to improve detection of previously undiagnosed atrial fibrillation
iRhythm Technologies has announced primary results of the mHealth Screening to Prevent Strokes (mSToPS) study that evaluated detection of silent atrial fibrillation (AF) in...
US Patent Office allows AblaCor five ablation catheter-anchoring patents
AblaCor medical corporation has announced that it has received a notice of allowance from the United States Patent & Trademark Office on five additional patents for...
CardioFocus announces initiation of HeartLight X3 clinical evaluation
CardioFocus have announced the initiation of a clinical evaluation of the new HeartLight X3 system for the treatment of AF.
Building upon the advanced features of the...
Short-term DAPT is feasible for patients undergoing percutaneous LAA closure
Felix Weise (Cardioangiologisches Centrum Bethanien, Frankfurt, Germany) and others report in EuroIntervention that a strategy of six weeks’ duration of dual antiplatelet therapy (DAPT)...
Cardiva Medical brings total financing round to US$41 million
Cardiva Medical, an innovator in the field of vascular closure, has announced that the company has closed on US$11 million in additional financing –...
Association found between left atrial appendage closure and readmission for thromboembolism
A collaborative study, has found that older patients with atrial fibrillation (AF) undergoing cardiac surgery accompanied with surgical left atrial appendage closure had a...
New data demonstrates >90% year 1 success rate for radiofrequency ablation in treating patients...
Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...
Acesion Pharma receives approval for Phase I study in atrial fibrillation
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arr